human itgb6 antibody (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
human itgb6 antibody
Human Itgb6 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human itgb6 antibody/product/R&D Systems
Average 94 stars, based on 7 article reviews
Human Itgb6 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human itgb6 antibody/product/R&D Systems
Average 94 stars, based on 7 article reviews
human itgb6 antibody - by Bioz Stars,
2026-03
94/100 stars
Images
1) Product Images from "ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma"
Article Title: ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma
Journal: bioRxiv
doi: 10.1101/2024.04.18.590156
Figure Legend Snippet: (A) Human Protein Atlas analysis of RNA expression of ITGB6 across various cancer types. Normalized RNA expression levels are given in fragments per kilobase million (FPKM). Data are acquired from TCGA. Graphs show the mean and SD. ( B) Differential gene expression analysis of ITGB6 across tumor and normal tissue. Data are obtained from a standardized concatenated data set from GEO, GTex, TCGA, and TARGET databases. RNA-seq tumor and normal tissue samples are obtained from the same patients and from adjacent sites. Graphs were generated using the TNMplot tool and were normalized using DESeq2. Fold-change (FC) of medians and Mann-Whitney test p-values are shown.
Techniques Used: RNA Expression, Gene Expression, RNA Sequencing, Generated, MANN-WHITNEY
Figure Legend Snippet: (A) ITGB6 RNA of selected human cancer cell lines from the Human Protein Atlas. (B) Flow cytometry analysis of the percentage of cancer cells that are ITGB6+ based on unstained controls. (C) Western blot validation of the CRISPR knockout of ITGB6 in FaDu and CAL27 cells. (D) Colony formation assay of CRISPR control (CTRL) cells and ITGB6 knockouts (KO-1) for FaDu and CAL27 cells. (E) Quantification of colony formation assay. Statistical analysis was performed using an unpaired t-test. Randomly chosen fields of view from the co-culture of FaDu (F) or CAL-27 (G) HNSCC cells (green) and TALL-104 T-cells (blue) (n = 10). Cells were pretreated for 8 hrs with latent TGFβ. Quantification of cancer cell counts for FaDu (H) and CAL27 (J). Quantification of the percentage of cancer cells that are dead for FaDu (I) and CAL27 (K). One-way ANOVA: p < 0.0001 (****), p < 0.002 (**).
Techniques Used: Flow Cytometry, Western Blot, Biomarker Discovery, CRISPR, Knock-Out, Colony Assay, Control, Co-Culture Assay
Figure Legend Snippet: (A) Flow cytometry analysis of the percentage of mouse cancer cells that are ITGB6+ based on unstained controls. (B) Western blot validation of CRISPR knockdown of ITGB6 in MOC1 and KPCY cells. (C) Colony formation assay of CRISPR control (CTRL) cells and ITGB6-knockout (KO-1, KO-2) cells for MOC1 and KPCY cells. (D) Quantification of colony formation assay. Statistical analysis was performed using one-way ANOVA: p < 0.05 (*). (E) Experimental timeline for C57BL/6 mice injected with syngeneic tumor cells. Tumor volume of mice starting upon tumor formation at day 5 for MOC1 (F) and KPCY (H) cohorts (n = 10). Mass of MOC1 (G) and KPCY (I) tumors harvested at day 25. Statistical comparison between CTRL and KO-1 cohorts was performed using an unpaired t-test: p < 0.001 (***), p < 0.05 (*).
Techniques Used: Flow Cytometry, Western Blot, Biomarker Discovery, CRISPR, Knockdown, Colony Assay, Control, Knock-Out, Injection, Comparison
Figure Legend Snippet: Curves show the overall survival of patients with various cancer types stratified based on ITGB6 expression. Patients with high ITGB6 have expression levels above +0.25 σ of the mean and ITGB6 low patients have expression below -0.25 σ. The graphs were generated using TCGA data through the cBioPortal. Statistical analysis of Kaplan-Meier curves and corresponding hazard ratios (HR) was performed using the Log-rank test.
Techniques Used: Expressing, Generated
Figure Legend Snippet: (A) Pan-cancer analysis of ITGB6 RNA expression level normalized using DESeq2 of patients who are either responsive or unresponsive to immune checkpoint blockade. RNA data are extracted from a TCGA data set of multiple cancer types of patients who underwent immune checkpoint blockade therapy. Graphs were generated using the ROCplot tool and the results of an unpaired t-test are shown. (B) Kaplan-Meier curves of overall survival of patients undergoing immune checkpoint blockade therapy stratified into low and high ITGB6 expression about the mean. Statistical analysis was performed using the Log-rank test.
Techniques Used: RNA Expression, Generated, Expressing
